PITAJTE DOKTORA

ZA BESPLATNE SAVJETE NAZOVITE dr.med. DIJANU HEDER

tel. 01.4881600, 0994466551, info@eurovita.ch, WhatsApp, Viber: 0994466551

Imunoterapija za specifične vrste raka

FDA (Food and Drug Administration) odobrila je niz imunoterapija za rak, uključujući Bakcil Calmette-Guerin (BCG), interferon-alfa (IFN-alfa), interleukin-2 (IL-2), sipuleucel-T (Provenge) cjepivo i nekoliko monoklonalnih antitijela. Mnoge su druge imunoterapije pokazale obećavajuće rezultate i kreću u proces testiranja kroz klinička ispitivanja.

By admin

18/12/2014

 

 

Vrste raka sljedećim postovima intenzivnije se proučavaju, ali se istražuju i tretmani za druge vrste raka.

 

REFERENCE

 

Ault KA, Future II study group. Effect of prophylactic human papillomavirus L1 viruslike-particle vaccine on risk of cervical intraepithelial neoplasia grade 2, grade 3, and adenocarcinoma in situ: a combined analysis of four randomised clinical trials. Lancet.

2007;369:1861−1868

 

Bast RC, Zalutsky MR, Kreitman RJ, Frankel AE. Monoclonal serotherapy. In: Kufe DW, Bast RC, Hait WN, Hong WK, Pollock RE, Weichselbaum RR, Holland JF, Frei E, eds. Cancer Medicine 7. Hamilton, Ontario: BC Decker, Inc.;2006:770−785.

 

Burris HA 3rd, Rugo HS, Vukelja SJ, et al. Phase II study of the antibody drug conjugate trastuzumab-DM1 for the treatment of human epidermal growth factor receptor 2 (HER2)-positive breast cancer after prior HER2-directed therapy. J Clin Oncol. 2011;29:398-405.

 

Chen R, Gopal AK, Smith SE, et al. Results of a pivotal phase 2 study of brentuximab vedotin (SGN-35) in patients with relapsed or refractory Hodgkin lymphoma. Blood (ASH Annual Meeting Abstracts), Nov 2010;116:283.

 

Chesney J, Rasku M, Clem A, Miller D. Denileukin diftitox depletes T regulatory cells and causes regression of melanoma metastases in humans [abstract]. Eur J Cancer Suppl. 2006;4:12:84.

 

Disis ML, Grabstein KH, Sleath PR, Cheever MA. Generation of immunity to the HER-2/neu oncogenic protein in patients with breast and ovarian cancer using a peptide-based vaccine. Clin Cancer Res. 1999;5:1289−1297.

 

Dudley ME, Wunderlich JR, Robbins PF, et al. Cancer regression and autoimmunity in patients after clonal repopulation with antitumor lymphocytes. Science.

2002;298:850−854.

 

Ekmekcioglu S, Grimm EA, Kurzrock R. Cytokines and hematopoietic growth factors. In: Kufe DW, Bast RC, Hait WN, Hong WK, Pollock RE, Weichselbaum RR, Holland JF, Frei E, eds. Cancer Medicine 7. Hamilton, Ontario: BC Decker, Inc.;2006:744–769.

 

Higano CS, Schellhammer PF, Small EJ, et al. Integrated data from 2 randomized, double-blind, placebo-controlled, phase 3 trials of active cellular immunotherapy with sipuleucel-T in advanced prostate cancer. Cancer. 2009;115:3670−3679.

 

Hodge JW, Schlom J, Abrams SI. Vaccines and immunostimulants. In: Kufe DW, Bast RC, Hait WN, Hong WK, Pollock RE, Weichselbaum RR, Holland JF, Frei E, eds. Cancer Medicine 7. Hamilton, Ontario: BC Decker, Inc.;2006:786–801.

 

Hodi FS, O’Day SJ, McDermott DF, et al. Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med. 2010;363:711−723.

 

Hsueh EC, Nathanson L, Foshag LJ, et al. Active specific immunotherapy with polyvalent melanoma cell vaccine for patients with in-transit melanoma metastases. Cancer. 1999;85:2160−2169.

 

Kreitman RJ, Wilson WH, Bergeron K, et al. Efficacy of the anti-CD22 recombinant immunotoxin BL22 in chemotherapy-resistant hairy-cell leukemia. N Engl J Med. 2001;345:241−247.

 

Morgan RA, Dudley ME, Wunderlich JR, et al. Cancer regression in patients after transfer of genetically engineered lymphocytes. Science. 2006;314:126−129.

Morse MA, Clay TM, Lyerly HK. Handbook of Cancer Vaccines. Totowa NJ: Humana Press, 2004.

 

Nemunaitis J, Sterman D, Jablons D, et al. Granulocyte-macrophage colony-stimulating factor gene-modified autologous tumor vaccines in non-small-cell lung cancer. J Natl Cancer Inst. 2004;96:326−331.

 

Restifo NP, Robbins PF, Rosenberg SA. Principles of immunotherapy. In: DeVita VT, Hellman S, Rosenberg SA, eds. Cancer: Principles and Practice of Oncology. 8th ed. Philadelphia, Pa: Lippincott Williams & Wilkins;2008:351−368.

 

Robbins PF, Morgan RA, Feldman SA, et al. Tumor regression in patients with metastatic synovial cell sarcoma and melanoma using genetically engineered lymphocytes reactive with NY-ESO-1. J Clin Oncol. 2011;29:917−924.

 

Robinson MK, Borghaei H, Adams GP, Weiner LM. Monoclonal antibodies. In: DeVita VT, Hellman S, Rosenberg SA, eds. Cancer: Principles and Practice of Oncology. 8th ed. Philadelphia, Pa: Lippincott Williams & Wilkins;2008:537−548.

 

Salgaller ML. Immune adjuvants. In: Rosenberg SA, ed. Principles and Practice of the Biologic Therapy of Cancer. 3rd ed. Philadelphia, Pa: Lippincott Williams &

Wilkins;2000:584−601.

 

DODATNI RESURSI:

 

National Cancer Institute

Web stranica: www.cancer.gov
Besplatni broj: 1-800-4- CANCER

 

Što čitati dalje ...

Slovenski liječnici: potpunom legalizacijom konoplje suzbiti rast crnog tržišta

UN: Mala je vjerojatnost da je glifosat kancerogen

>

 

2017  © d.istra